

EUROPEAN CURRICULUM VITAE

PERSONAL INFORMATION

Name	Massimino Michele
Address	Via Giuseppe Ungaretti 35/F, Aci Sant' Antonio, 95025 (CT)
Telephone	340-2506835
Fax	
E-mail	michedot@yahoo.it
Nationality	Italy
Date of birth	December 7th, 1974

WORK EXPERIENCE-Actual Position

Dates (from - to)	From, 2012
PI	Professor Francesco Di Raimondo, General Hospital Policlinico-Vittorio Emanuele. Hematology, Ferrarotto Via Citelli 31. 95100 Catania Italy.
Principal subjects-occupational skills covered	<ul style="list-style-type: none"> • Biological characterization of nuclear import/export signals of the human BCR and ABL proteins; • Clinical study of the anti-apoptotic role of the BCR-ABL oncoprotein in CML cells; • Clinical study of the functional interaction between IRF-5 and BCR-ABL. • Implementation and development of a gene bank of nucleic acids from bone marrow of patients with acute and chronic leukemias
Title of qualification awarded	Post-Doctoral Fellow in Molecular and Cellular Biology.

WORK EXPERIENCE

Dates (from - to)	2014
PI	Professor Sebastiano Squadrito, University of Catania, Department of Clinica and Molecular Biomedicine. Via Palermo 636 95122 Catania, Italy.
Principal subjects-occupational skills covered	<ul style="list-style-type: none"> • Molecular mechanism controlling cancer stem cells survival • Analysis of endogenous Insulin Receptor (IR) in Mouse Fibroblast. • IR gene silencing by doxycycline inducible shRNA using lentiviral particles. • Cloning and expression of Insulin Receptor isoforms (IR-A, IR-B) by lentiviral vector with doxycycline inducible promoter. • Evaluation of apoptosis and cellular proliferation after exposure of cytotoxic agents in these models.
Title of qualification awarded	Post-Doctoral Fellow in Molecular and Cellular Biology.

WORK EXPERIENCE

Dates (from - to)	From January 1, 2010
--------------------------	----------------------

PI	Paolo Vigneri, Department of Clinical and Molecular Bio-Medicine, University of Catania, Via Androne 85, 95124 Catania
Principal subjects-occupational skills covered	<ul style="list-style-type: none"> • Biological characterization of nuclear import/export signals of the human BCR and ABL proteins; • Clinical study of the anti-apoptotic role of the BCR-ABL oncoprotein in CML cells; • Clinical study of the functional interaction between IRF-5 and BCR-ABL.
Title of qualification awarded	Post-Doctoral Fellow in Molecular and Cellular Biology.

WORK EXPERIENCE

Dates (from - to)	From May 7, 2005 to December 31, 2009
PI	Paolo Vigneri, Department of Biomedical Sciences, Section of General Pathology, University of Catania, Via Androne 83, 95124 Catania
Principal subjects-occupational skills covered	<ul style="list-style-type: none"> • Monitoring of the BCR-ABL transcript by Real-Time PCR in CML patients; • Role carried of IAPs and Smac/Diablo in the chemoresistance of thyroid cancer cells; • Clinical study of the antiapoptotic role of the BCR-ABL oncoprotein in CML cells; • Role of the IRF-5 protein in thyroid cancer cells; • Biological evaluation of the cytotoxic effects of the immunoconjugate Inotuzumab in B-cell lymphoma.
Title of qualification awarded	Post-Doctoral Fellow in Molecular and Cellular Biology.

EDUCATION AND TRAINING

Name and type of organization providing education and training	Specialization in Pharmacology. From November 1, 2005 to October 31, 2008 Department of Pharmacology, Faculty of Medicine - University of Catania
Main subjects and professional skills related to the education awarded	Study of pharmacology, toxicology, medical statistics and major disorders of the CNS.
Title and professional qualification obtained	Pharmacology Specialist
Name and type of organization providing education and training	Ph.D. in Pharmaceutical Sciences, University of Catania, Faculty of Pharmacy, Department of Pharmaceutical Sciences, V.le A. Doria, 6, 95125 Catania Italy, 26 February 2004. Prof. Giuseppe Ronsisvalle.
Main subjects and professional skills related to the education awarded	Experiment design ability, organic synthesis, purification and characterization of the synthesised products (NMR, IR), binding assays techniques <i>in vitro</i> for the sigma-1/2, opioid m, d and k receptors, development of binding assay techniques in order to estimate the acetylating ability of an irreversible ligand towards a specific protein. The binding affinities of the ligands have been estimated through a competition assay using a high affinity radioligand for the considered protein. Doctoral thesis: Design, synthesis and binding assay of 3-(w-aminoalkyl)-1H-indoles as sigma-1 and sigma-2 receptors ligands.
Title and professional qualification obtained	Ph.D. in Pharmaceutical Science.
Name and type of organization providing education and training	Pharmacy degree (110/110 cum laude). University of Catania, Department of Pharmaceutical Sciences, Pharmacology Sec. V.le A. Doria, 6, 95125 Catania Italy. March 29, 2000.
Main subjects and professional skills related to the education awarded	Technique of i.c.v., i.p. and s.c. administrations, tail flick test, formalin test. Experimental Thesis: Modulation of Cholecystokinin on the antinociceptive effects of morphine in inflammatory pain from formalin in the rat. Tutor Professor C. Spadaro.

PERSONAL SKILLS AND EXPERTISE

Acquired in the course of life and career but not necessarily covered by formal certificates and diplomas

Other languages	English	LANGUAGES Intermediate English, Second Intermediate Certificate “The Language Centre of Ireland, Dublin”.	
Reading skills	Sufficient		
Writing skills	Basic		
Verbal skills	Basic		

Technical skills and expertise In Pharmaceutical Science (1) and In Molecular and Cellular Biology (2)	<p>(1)</p> <ul style="list-style-type: none"> - Organic Synthesis; - Design ability in organic chemistry; - Purification and characterization of the synthesised products (NMR, IR); - Binding assay <i>in vitro</i>; - Binding affinities of different ligands <p>(2)</p> <ul style="list-style-type: none"> - DNA Cloning of Plasmid and Lentiviral vectors; - Transfection and lentiviral infection of immortalized and primary cells; - RT-PCR and PCR Mutagenesis Reaction; - RT-QPCR; - Probe and Primer Design; - Western blot, Subcellular fractionation and Immunoprecipitation assays; - Immunofluorescence; - Pharmacological evaluation of cytotoxic agents; - FACS analysis (cell staining, cell cycle), Annexin V assays; - Luciferase Reporter Assay; - Immortalized and primary cell cultures; - Isolation and culture of CD34+ progenitor from donors; - LTC-IC assay - Methylcellulose assays - His-Tag Protein isolation - In vitro assay to evaluate the catalytic enzyme activity (V_{max}/K_m, Michelis_Menten)
Computer, special machineries and devices	<ul style="list-style-type: none"> - Win. 98 - Win. XP and MacOSX operating systems. - ChemOffice, ACDLabs, Isis Draw, Word, Excel, Power Point, Freehand, Corel Draw, Photoshop, Oligo 6, Gene Works.
Stage	<p>Pharmacia Italy S.p.A. Corporation Research Center, Nerviano (MI) Italy: Course of Medicinal Chemistry, Chemistry Department, 20-24 May 2002.</p> <p>XXI-XXII-XXIII Advanced School in Pharmaceutical Chemistry “E. Duranti”, Urbino. July 2001-2002-2003</p>
Acknowledgment	<p>April 2001</p> <ul style="list-style-type: none"> • Pharmacist Order of the Province of Catania, allocation prize for the best experimental thesis, academic year 1998/99. <p>February 2006</p> <ul style="list-style-type: none"> • Young Scientists Award in Oncology delivered by Accademia Gioenia, CT
Publications	<p>PUBLICATIONS</p> <p>SYNTHESIS OF BNIT AN ISOTHIOCYANATE DERIVATIVE OF N-BENZYL-NORMETAZOCINE AS ACYLANT AGENT FOR SIGMA/1 RECEPTOR. G. Ronsisvalle, O. Prezzavento, T. Marrazzo, F. Vittorio, <u>M. Massimino</u>, G. Murari, and S. Spampinato. <i>J. Med. Chem.</i> 45, 2662-2665, 2002</p> <p>ALTERED EXPRESSION OF C-IAP1, SURVIVIN, AND SMAC CONTRIBUTES TO CHEMOTHERAPY RESISTANCE IN THYROID CANCER CELLS. Elena Tirrò, Maria Letizia Consoli, <u>Michele Massimino</u>, Livia Manzella, Francesco Frasca, Laura Sciacca, Luisa Vicari, Giorgio Stassi, Luigi Messina, Angelo Messina, and Paolo Vigneri <i>Cancer Res</i> 2006 66: 4263-4272.</p> <p>SEQUENTIAL MUTATIONS CAUSING RESISTANCE TO BOTH IMATINIB</p>

MESYLATE AND DASATINIB IN A CHRONIC MYELOID LEUKAEMIA PATIENT PROGRESSING TO LYMPHOID BLAST CRISIS. Stagno F, Stella S, Berretta S, Massimino M, Antolino A, Giustolisi R, Messina A, Di Raimondo F, Vigneri P. *Leuk Res.* 2007 Sep 21;

IMATINIB DOSE ESCALATION TO ACHIEVE MOLECULAR RESPONSES IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN LATE CHRONIC PHASE. Stagno F, Vigneri P, Del Fabro V, Stella S, Massimino M, Berretta S, Messina A, Di Raimondo F. *Leuk Res.* 2008 Nov 24

SUCCESSFUL NILOTINIB THERAPY IN AN IMATINIB-RESISTANT CHRONIC MYELOID LEUKEMIA PATIENT DISPLAYING AN INTRON-DERIVED INSERTION/TRUNCATION MUTATION IN THE BCR-ABL KINASE DOMAIN. F. Stagno, P. Vigneri, V. Del Fabro, S. Stella, M. Massimino, S. Berretta, A. Cupria, C. Consoli, L. Messina, E. Tirrò, A. Messina, F. Di Raimondo. *Leukemia Research* 4 February 2009.

UNCOMMON LONG-TERM SURVIVAL IN A PATIENT WITH CHRONIC MYELOID LEUKEMIA. Stagno F, Vigneri P, Stagno F, Vigneri P, Del Fabro V, Stella S, Berretta S, Massimino M, Tirrò E, Messina A, Di Raimondo F. *Acta Oncol.* 2009;48(8):1215-6.

CONCOMITANT AND FEASIBLE TREATMENT WITH DASATINIB AND THE ANTI-EGFR ANTIBODY CETUXIMAB PLUS RADIOTHERAPY IN A CML PATIENT WITH MULTIPLE SQUAMOUS NEOPLASIAS. Stagno F, Vigneri P, Fabro VD, Stella S, Restuccia N, Giallongo C, Massimino M, Berretta S, Pennisi MS, Tibullo D, Tirrò E, Buscarino C, Messina A, Raimondo FD. *Acta Oncol.* 2009 Oct 20

INFLUENCE OF COMPLEX VARIANT CHROMOSOMAL TRANSLOCATIONS IN CHRONIC MYELOID LEUKEMIA PATIENTS TREATED WITH TYROSINE KINASE INHIBITORS. Stagno F, Vigneri P, Del Fabro V, Stella S, Cupri A, Massimino M, Consoli C, Tambè L, Consoli ML, Antolino A, Di Raimondo F. *Acta Oncol.* 2010 May;49(4):506-8.

UNSUCCESSFUL DASATINIB THERAPY IN A REFRACTORY PATIENT WITH CHRONIC LYMPHOCYTIC LEUKEMIA. Stagno F, Vigneri P, Del Fabro V, Fidilio A, Spina P, Massimino M, Messina A, Di Raimondo F. *Acta Haematol.* 2010;124(2):103-4. Epub 2010 Aug 3.

HYPERDIPLOIDY ASSOCIATED WITH A HIGH BCR-ABL TRANSCRIPT LEVEL MAY IDENTIFY PATIENTS AT RISK OF PROGRESSION IN CHRONIC MYELOID LEUKEMIA. Stagno F, Vigneri P, Consoli ML, Cupri A, Stella S, Tambè L, Massimino M, Manzella L, Di Raimondo F. *Acta Haematol.* 2012;127(1):7-9. Epub 2011 Oct 5.

IRF5 PROMOTES THE PROLIFERATION OF HUMAN THYROID CANCER CELLS. Massimino M, Vigneri P, Fallica M, Fidilio A, Aloisi A, Frasca F, Manzella L. *Mol Cancer.* 2012 Apr 16;11(1):21.

BCR-ABL RESIDUES INTERACTING WITH PONATINIB ARE CRITICAL TO PRESERVE THE TUMORIGENIC POTENTIAL OF THE ONCOPROTEIN. Buffa P, Romano C, Pandini A, Massimino M, Tirrò E, Di Raimondo F, Manzella L, Fraternali F, Vigneri PG. *FASEB J.* 2013 Dec 2.

IRF5 IS A TARGET OF BCR-ABL KINASE ACTIVITY AND REDUCES CML CELL PROLIFERATION. Massimino M, Consoli ML, Mesuraca M, Stagno F, Tirrò E, Stella S, Pennisi MS, Romano C, Buffa P, Bond HM, Morrone G, Sciacca L, Di Raimondo F, Manzella L, Vigneri P. *Carcinogenesis.* 2014 Jan 20.

KNOCKOUT SERUM REPLACEMENT PROMOTES CELL SURVIVAL BY PREVENTING BIM FROM INDUCING MITOCHONDRIAL CYTOCHROME C RELEASE. Ishii Y, Nhaiyi MK, Tse E, Cheng J, Massimino M, Durden DL, Vigneri P, Wang JY. *PlosOne.* 2015 Oct 16.

THE INSULIN/IGF SYSTEM IN COLORECTAL CANCER DEVELOPMENT AND RESISTANCE TO THERAPY. Vigneri PG, Tirrò E, Pennisi MS, Massimino M, Stella S, Romano C, Manzella L. *Front*

Oncol. 2015 Oct 15;5:230 (Review).

ROLES OF INTERFERON REGULATORY FACTORS IN CHRONIC MYELOID LEUKEMIA.

Livia Manzella, Elena Tirrò, Maria Stella Pennisi, Michele Massimino, Stefania Stella, Chiara Romano, Silvia Rita Vitale and Paolo Vigneri. Current Cancer Drug Targets (Review). Under Revision

Catania 10/11/2015

F.to Michele Massimino

Il sottoscritto Michele Massimino esprime il proprio consenso affinché I dati personali forniti possano essere trattati, nel rispetto del D. Lgs.196/2003 e successive modifiche.

IL PRESENTE CURRICULUM VITAE VIENE RESO QUALE DICHIARAZIONE SOSTITUTIVA DELL'ATTO DI NOTORIETA', AI SENSI DELL'ART. 47 DEL D.P.R. 28.12.2000, N. 445.